Two novel device or indication approvals were added to Medtech Insight's Approvals Tracker last week. Among them, Tandem Diabetes Care Inc. netted a first with US FDA. On Feb. 14, the agency granted a de novo classification to a version of Tandem's t:Slim X2 insulin pump with technology allowing it to be used with a variety of different components that make up diabetes therapy systems.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?